Wall Street: Money Never Sleeps Marketwatch's Article and Movie Trailer

Image via Wikipedia  Did Stone go too far with Gekko?
Commentary: Stone wanted Gekko to ask himself tough questions

By David Weidner, MarketWatch

NEW YORK (MarketWatch) — For a generation of Wall Street bankers, the symbol of the perfect investment banker wasn’t any flesh-and-blood individual in the industry, it was Michael Douglas.

Douglas reprised his role as Gordon Gekko in “Wall Street: Money Never Sleeps,” which opened last weekend and was the top box-office draw, grossing more than $19 million. The movie, like the industry in which it’s set, seems to have prospered from a lack of meaningful competition.

Seattle Genetics Announces Pivotal Results in Lymphoma Drug Trial

Image via WikipediaLymphoma news from Seattle Genetics hitting the web. This company is really making strides with Non-Hodgkin's Lymphoma drug Brentuximab. This drug is partnered with Takeda Oncology's Millennium. Takeda is a global pharmaceutical firm who specializes in Clinical Trials and marketing on a global scale. Brentuximab elicited 75% response rate in patients that had already rejected other cancer drugs, which is common.

Novartis Gains FDA Approval For Oral MS Drug

Image via WikipediaNovartis is now a game changer in MS market. Novartis is usually known for their vaccines, is the first in the oral pill MS drug market. Top News from Novartis as MS drug, Gelenya was approved from the FDA Monday.

Wikinvest: Novartis AG (NVS)

BSD Medical's Stock is Rising Fast: BSDM

BSD Medical is going up like hotcakes these days. I still think there is plenty of room for future growth. Today's trading is BSDM 3.16 +0.19 (6.40%) They recently had FDA approval for cancer treatment medical device. I don't think it's too late to get on board with this stock and see it as a real Long Term Growth Potential. They are selling their newly acquired 510K approved products at a rapid pace to Cancer Treatment centers across the country.

Wikinvest is a great Market Tool: BSD Medical




Texas Oncology Acquires Hyperthermia System from BSD Medical

Chelsea Therapeutics Rockets Upward on Clinical Trial Data

Image via Wikipedia So yesterday I was cautiously optimistic on Chelsea Therapeutics' 2nd go around with their Phase III Clinical Trial and I will eat crow on that story. I am simply a cautious investor. There is nothing wrong with that. I just want the facts before I jump into an investment.

But if the story had gone the other way, people would have lost a lot of money today upon negative results. I just wasn't so sure it would work this time around. I see now that it will be a good run-up candidate pending FDA approval. The stockcould go down a little after all the hoopla today and when it hits a bottoming price I see it as a buy. I'm not so sure I would be buying it just yet as there will be some selloff after today's news but putting a limit price target on the stock could be a good idea.

Most of the trading was done by Wall Street Investors in Pre-Market hours, so if you bought it this morning you might have lost a small chunk of change. Wall St. has a funny way of controling things before and after trading hits the floor for the everyday investor. They like to control the floor and let the little guy suffer sometimes. I won't go too much into that but you have to be careful when playing with the big boys in this game. Today is a good example if you look at todays stock chart.

Google Finance: CHTP

Here is the news today.

Chelsea Therapeutics 2nd Clinical Trial Pending Results

Image via CrunchBase

From Wikinvest: Chelsea Therapeutics (CHTP) traded higher Friday closing at 5.06 +0.94 for a 22% gain. I am showing some caution for Chelsea Therapeutics as this Clinical Trial was previously rejected last September. News from that rejection from Sept. 2009: Chelsea Therapeutics (CHTP) Dives After Trial Did Not Demonstrate Statistically Significant Improvement Versus Placebo. For more information on the 2009 Clinical Trial you can read more about it here: Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension

The catalyst that pushed Chelsea higher this past Friday was based on an Upgrade of Chelsea pending a 2nd Phase III clinical trial results.

Alkermes Gains FDA Recommendation For Vititrol

Cover of The Treatment of Opioid Dependence I expect a huge day tomorrow for Alkermes with the FDA recommendation of Vivitrol. PFUDA is Oct. 12, 2010. I expect approval with Vivotrol but you can never be sure with the FDA. Again big day tomorrow for Alkermes.

Wikinvest---Alkermes (ALKS)

Alkermes Announces FDA Advisory Committee Recommends Approval Of VIVITROL® For Opioid Dependence

Alkermes, Inc. (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL ^® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence. Alkermes, Inc. (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL ^® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence.

FDA rejects Arena's Lorcaserin, Stock Plunges

If you may have noticed, I haven't covered the weight loss drug companies since the panel rejected Vivus' Qnexa. Vivus (VVUS), Orexigen (OREX), and Arena (ARNA) are all horrible stock plays right now with the Ultra Conservative FDA board under the Obama administration right now. Sure the drugs might work., but the FDA isn't going to approve anything that might have any hint of a safety concern. Today is a good example of why that is true.

Rodman & Renshaw: Promising Biotechs from TheStreet

I was really impressed by Adam Feuerstein's article in TheStreet today. The Rodman Investor's Conference showcases promising upcoming Biotech and Pharmaceutical companies.
Stocks mentioned in this article are: AVII, BDSI, DNDN, RXII, ATHX, NEOL, PYMX

Rodman Rambles: Promising Biotechs

NEW YORK (TheStreet) -- I saw some promising, small biotech companies at this week's Rodman & Renshaw Annual Global Investment Conferences. The confab wasn't all about the biotech dreck---i.e. Biotech losers.

Savient Pharma Soars on FDA Approval For Gout Treatment



Gout Uric Acid Crystals



From the Wall Street Journal and Reuters: Savient Pharmaceuticals

Wikinvest: (SVNT) Google Finance (SVNT)

Savient shares rally as FDA approves gout drug
Sept 15
Wed Sep 15, 2010 9:15am EDT

The approval is also expected to trigger a renewed interest in the company that has been looking for a strategic deal, and some analysts expect a deal within three to four months.

Savient Soars On Gout Treatment Approval While Arena Slumps On Weight Loss

Image via Wikipedia

Market Pulse
Sept. 15, 2010, 1:14 p.m. EDTSavient shares soar on FDA gout treatment approval

SAN FRANCISCO (MarketWatch) -- Shares of Savient Pharmaceuticals Inc. (SVNT 20.23, +0.25, +1.24%) jumped Wednesday after the biotech company said the Food and Drug Administration approved its gout treatment. Savient shares rose 29% to $19.09 in recent trading. The FDA approved Savient's Krystexxa for the treatment of hard-to-treat gout in adults. Gout is a type of arthritis where uric acid crystallizes in the joints causing inflammation and pain. Savient expects Krystexxa to be available on the U.S. market later in the year, and said the drug is protected by patents out to 2026

Biotech Stocks

Sept. 14, 2010, 1:11 p.m. EDT

Arena plunges on FDA news; drug indexes climb

Seattle Genetics Reports Disappointing Phase II Data For AML, and Upcoming Clinical Trial Results for NHL

Wikinvest-Seattle Genetics (SGEN)

Disappointing news reported from Seattle Genetics today. I actually like the stock after the price bottoms out as they are focusing their efforts on Non-Hodgkins Lymphoma drug, brentuximab.  Wait for the massive sell-off in the next week or two and wait for Clinical Trials results to come out in about 6 weeks from Phase II testing for NHL.  I anticipate a massive sell-off in the next couple of days after todays disappointing clinical trials news on a separate medication for AML, acute myeloid leukemia.

KEYWORDS: Antibody-Drug Conjugates, Millenium Pharmaceuticals, Seattle Genetics, AML, Monoclonal Antibody Therapeutics, Hodgkin Lymphoma

Seattle Genetics is ditching further development of its clinical-stage acute myeloid leukemia (AML) candidate lintuzumab (SGN-33) after a Phase IIb trial failed to show the drug extended overall survival. The firm says it will now focus on the rest of its clinical pipeline, headed by the Phase III-stage Hodgkin lymphoma drug, brentuximab vedotin, which is being developed in collaboration with Millennium Pharmaceuticals.

Warren Buffet's Berkshire Hathaway Buying Johnson and Johnson, Becton Dickinson

Image via Wikipedia

How many times has Warren Buffett been wrong?  If Buffett is buying Johnson & Johnson, that makes it a buy.  Even with the whole Tylenol fiasco, I think it is oversold.  

Billionaire Warren Buffett's Berkshire Hathaway has been quietly buying shares of Johnson & Johnson, and Becton Dickinson at an astonishing rate.  This endorsement from Omaha, Nebraska's famous billionaire, The Oracle from Omaha, has made these stocks a buy.

Warren Buffett Biography:  The Story of Berkshire Hathaway's Billionaire Chairman

The Snowball:  Warren Buffett and the Business of Life

JNJ at a discount


If you would like more Subscribe To BioPharma Investor for everyday stock news and up to date FDA decisions.  Biopharma Investor

Ariad and Cyclacel To Start Clinical Trials for Blood Cancer Drugs for Leukemia

Image via Wikipedia From The Street's Adam Feuerstein

Ariad, Cyclacel To Start Key Drug Trials


Stock quotes in this article:ARIA, CYCC, SGEN, NVS, BMY

Questcor: FDA Delays Drug Approval

Try WikInvest Here----> http://www.wikinvest.com/wiki/QCOR

Stocks Mentioned in this article: QCOR

Questcor: FDA Delays Drug Approval

Questcor announced late Wednesday that the U.S. Food and Drug Administration has delayed for the second time an approval decision for the company's drug Acthar as a treatment for infantile spasms.

A new approval date has not been announced but Questcor said FDA's review will extend beyond the current Sept. 11 deadline because regulators need more time to finalize the wording on the label, review the proposed medication guide, and define post-approval commitments, if any, for the infantile spasms indication.

The Essential Biotech Sector Fall Preview

Try WikInvest Here:--;https://www.wikinvest.com/

Stock quotes in this article: DNDN, HGSI, GENZ, ARNA, AMLN, IDIX, PCYC

The Essential Biotech Sector Fall Preview

BOSTON (TheStreet) -- Labor Day is over and Hurricane Earl is out to sea, which means Wall Street is returning to work in earnest for the last three months of the year. To put everyone in the right mindset, I've compiled a "Back to School" guide covering the essential information biotech investors need to profit from what should be a very busy fall season.

Help Keep This Site Up and Running

Help keep this site bring everyone up to date BioPharma News for Free. Any donations made help keep this site free.  It only takes a second. Thanks For Your Continued Support. Again thank you as I am entering my Second Year of providing BioPharma Stock updates and advice.

Related articles by Zemanta

• What If You Could Click A Button And A Sponsor Would Pay A Site Money (Without It Being Clickfraud)? (techdirt.com)
• 5 Effective Ways to Maximize Ad Revenue on Your Blog (quickonlinetips.com)
• Get Click-By-Click Insight Into Your Site Visitors With MouseTrace (readwriteweb.com)

Bristol-Myers Acquires ZymoGenetics

Image via Wikipedia Healthcare Sector Breaking News for Tuesday, September 07, 2010

Bristol-Myers Squib to merge with ZymoGenetics

After the bell Tuesday, Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

Cancer Diagnostic Screening Top Emerging Companies: MabCure, Radient Pharmaceuticals, Exact Sciences

Another Cancer Diagnostic Test on my radar is MabCure, Inc., symbol (MBCI). I really like Cancer Diagnostic Testing stocks. They are difficult to find research on these companies and until the testing is approved they are serious cash cows, bleeding cash, and overcome by the dreaded Dilution of share price.

But once approved, this technology will increase investments ten-fold. They are highly profitable and the return on investment should be good for the companies' stocks. There is an increase in competition from new entrants and established companies. Top Tier companies include Myriad Genetics, Beckman Coulter, Roche, Siemens, Bio-Rad, and BD.

I focus on emerging testing markets currently seeking approval and MabCure fits that bill, along with Exact Sciences (EXAS), who is set to disclose their clinical trial Oct. 29, and Radient Pharmaceuticals (RPC) , who has their testing approved and is currently working on sales and validation of product.

For a quick list of all companies in the market visit the following link:

Worldwide Market for Cancer Diagnostics

This article was featured in Marketwatch on MabCure's technology.

MabCure, Inc. Announces Positive Results for New Ovarian Cancer Diagnostic Blood Test
Study Results Show 94 Percent Accuracy in Confirming Diagnosis of Ovarian Cancer

Is ArQule The Next Dendreon?

Image via Wikipedia This stock has been on my radar for a couple of months. Arqule could be the next Dendreon. It is a cash cow and needs a little more clinical trial data before I pull the trigger but I will continue to watch this stock. I will keep you up to date if anything changes. Currently AQ197 is entering Phase III clinical trials for non-small cell lung cancer with Japanese partner Daiichi Sankyo.

ArQule:  (ARQL)
Daiichi Sankyo:  (Tokyo: 4568)

ArQule's sky-high, but there still could be upside

By Val Brickates Kennedy, MarketWatch June 4, 2010

FDA Alert Questcor Pharma

FDA Decision Alert: Questcor Pharma

QCOR: Google Finance Profile

(RTTNews) - In less than a week, the Food and Drug Administration will take a final decision on Questcor Pharmaceuticals Inc.'s (QCOR) H.P. Acthar Gel for the proposed expanded indication of infantile spasms.

The regulatory agency was originally scheduled to rule on Acthar's expanded indication in June. But the deadline was extended in order to review information regarding labeling and potential post-approval commitments that they solicited from Questcor.

Forest Labs FDA Panel Review and Phase II Clinical Trial Results

Chemical Structure of Ceftaroline This just in to marketwatch today.

Forest-Gedeon Richter drug misses overall goal

TEL AVIV (MarketWatch) -- Forest Laboratories Inc. FRX 29.56, +0.37, +1.27%) and Gedeon Richter PLC said Monday that in a Phase II study of cariprazine, a potential treatment for bipolar depression, the overall result for patients taking the drug was not statistically different from that of the patients taking placebo. In higher doses, however, the antipsychotic drug did show "evidence of a clinically relevant treatment effect," the drugmakers, based respectively in New York and Budapest, said. The primary endpoint was the scores on the Montgomery Asberg Depression Rating Scale, they said. The companies are mulling whether to do another Phase II study of the drug to examine a wider range of doses. Meantime, the drug is in Phase III trials for, separately, schizophrenia and bipolar mania

News concerning Tomorrow's FDA decision. This is an antibiotic up for approval up for review tomorrow Sept. 7th, 2010.

FDA Panel Alert: Forest Labs

Comprehensive List of Drugs Approved During the Summer 2010

I found this nice list of 2010 drug approvals on The Health Wisdom Blog.  This probably is the most informative posting on Drug Approvals from 2010.


Glaxo (GSK), Merck (MRK), Novartis (NVS), Sanofi-Aventis (SNY), and Amgen (AMGN)  were again at the top on these approvals.

New Drugs Approved Summer 2010

New drugs not only offer hope, but possibly a better quality of life, for those awaiting new treatments. However, new drug approvals can also spark controversy. The FDA approved 17 new drugs this summer (June-August 2010). Many offer new promise, and one in particular promises a great deal of future debate.

Comprehensive List of Drug Approvals From 2009

Image by boodoo via Flickr I found a nice list of all the drugs approved in 2009 and their respectable companies.

Those of note were Glaxo SmithKline (GSK) with HPV vaccine, H1N1, seasonal flu vaccine, renal carcinoma, and lymphocyte leukemia.

Novartis (NVS) for H1N1, seasonal flu vaccine, MS, malaria, and schizophrenia.

Schering-Plough, now Merck (MRK) , for schizophrenia. Schering was bought out for their extensive drug pipeline of numerous upcoming drugs.

Sanofi-Aventis (SNY) had an antiarrhythmic drug, along with another flu vaccine for elderly patients. Sanofi is getting snuffed out with the Genzyme takeover bid but the bidding could still continue.

Others included Takeda Pharmaceuticals (TKPHF), Cypress Biosciences/Forest Labs, Allos Therapeutics, Lilly/Daiichi Sankyo, Gloucester Pharmaceuticals, and Theravance.

Please Help Keep This Site Free

Please helpkeep this site free. Help by making a donation to this site.  It only takes a second and helps me continue writing and gathering research for BioPharma Stocks. Sorry but sometimes you have to pay the bills. Thanks so much and I will continue to provide free stock research.  I won't steal your identity and this site is Spyware Free. 

Related articles by Zemanta

• Biotech Stocks in Spotlight (Orexigen Therapeutics, Inc., VIVUS, Inc., Cell ... - Benzinga (news.google.com)
• Beginner Advice on Online Stock Trading (shares-stocks.suite101.com)
• Stocks in Play for July 22 (AOB, MOT, SOMX) (wallstreetpit.com)

Forest Labs Antibiotic Seems Effective FDA Notes Revealed

Image via Wikipedia FDA staff back safety, efficacy of ceftaroline

* Advisory panel to review drug on Tuesday
* Forest shares up 5.4 pct in afternoon
* Nearly $361 million in ceftaroline sales seen in 2014 (Revises first sentence, adds analyst comment, updates shares)
By Lisa Richwine

WASHINGTON, Sept 2 (Reuters) - A Forest Laboratories Inc (FRX.N) antibiotic appears effective with risks similar to current options, U.S. drug reviewers said in an analysis that raised hopes for the medicine's approval.

Shares of Forest, which needs new medicines to offset looming patent expirations on its major drugs, were up $1.49 or 5.4 percent at $29.14 on the New York Stock Exchange after the Food and Drug Administration released its preliminary review on Thursday.

Analysts expect nearly $361 million in sales in 2014 for the potential new antibiotic called ceftaroline, according to Thomson Reuters forecasts.

FDA Advisory Panels Recommends Fewer Drugs This Year

Image via Wikipedia It has been a rough year for Drug Candidates this year. Time after time FDA panels are rejecting more qualified drug approvals. So what really is going on here. Are drug up for FDA approval less safe, less effective, or are the panels more cautious on approvals. These panels have had a devastating effect on the company's stock after these No recommendations. Let's take a closer look into what's really going on.

FDA Advisory Panels: A Coin Flip

Stock Rally Could Lead to Bond Bubble

Just a quick note of caution on Bonds right now. A bubble could be fast approaching. I wouldn't panic just yet as this is just one positive day in a bleak market, but more days like this and it would be time to sell those Bond ETFs. I moved some shares into Precious Metal Derivatives which have been doing quite well this year.

Note to Bond Bulls: Wednesday's Stock Rally Shows How Quickly Things Can Change
By VISHESH KUMAR Posted 6:00 PM 09/01/10

Wall Street greeted positive economic data from around the world with a sharp stock market rally to start September. And for most equity investors, the positive development provided a rare ray of sunshine following the most brutal August trading in nearly a decade.

But while stocks welcomed a respite from what some see as a bubble in pessimism, the turn of events should be just as unnerving to a fast-growing crowd of individual investors: those who have recently marshaled their savings into ultrasafe holdings like U.S. government bonds. Such folks saw their new investments take a sharp dive on Wednesday.


The jolt should serve as a reminder of how quickly things can change given the dear prices safe assets are commanding, and it could be a sign of things to come.

Revolutions Medical Safety IV and Syringe

Revolutions Medical RMCP 0.690 +0.191 acheives 38% gain

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. The Company also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

For additional information, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com/.

Fact Sheet:

http://content.stockpr.com/rmcp/files/RMCP+-+Fact+Sheet+02-26-10.pdf

News Today:

iCAD Veralook Colon Cancer Screening Technology

Image via Wikipedia I really like this stock for Long Term Growth Potential. iCAD

Good News for Biolase, Henry Schein Medical Systems

Image via Wikipedia Big News for Biolase today. Biolase is poised to make a profit now and increase their market cap which is currently, 19.41M.

Biolase has been bleeding cash and losing money this year. Annual Revenue is 43.35M and they reported a loss of 2.96M last year, however that was an improvement from a loss of 8.78M in 2008 and 8.97M in 2007. Revenue has been down from those two years.

In 3 years Biolase's stock has fallen from a high of 8/share to trading today at 0.80. Hopefully, this stock will rebound to its 2007 prices for large profits.